[
    [
        {
            "time": "2023-10-01",
            "original_text": "智飞生物向湖北捐款1000万元，助力新型冠状肺炎疫情防控",
            "features": {
                "keywords": [
                    "智飞生物",
                    "捐款",
                    "湖北",
                    "疫情防控"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智飞生物向湖北捐款1000万元，助力新型冠状肺炎疫情防控",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "深度：超大市场空间的结核病产品系列布局对智飞的意义几何 【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "智飞",
                    "结核病",
                    "产品布局",
                    "市场空间"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "深度：超大市场空间的结核病产品系列布局对智飞的意义几何 【国盛医药张金洋团队】",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "智飞生物：业绩持续高速增长符合预期，研发管线存预期差估值重塑持续推进【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩增长",
                    "研发管线",
                    "估值重塑"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：业绩持续高速增长符合预期，研发管线存预期差估值重塑持续推进【国盛医药张金洋团队】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "丽珠集团：丽珠微球平台国内第一，品种集中进入临床，研发进度加速【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "丽珠集团",
                    "微球平台",
                    "研发进度",
                    "临床试验"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "丽珠集团：丽珠微球平台国内第一，品种集中进入临床，研发进度加速【国盛医药张金洋团队】",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "智飞生物：业绩符合预期，预防接种已在快速恢复中【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩",
                    "预防接种",
                    "快速恢复"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：业绩符合预期，预防接种已在快速恢复中【国盛医药张金洋团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "智飞生物：业绩符合预期，关注重磅产品审批进度【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "智飞生物",
                    "业绩",
                    "重磅产品",
                    "审批进度"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：业绩符合预期，关注重磅产品审批进度【国盛医药张金洋团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]